semaj83/ctmatch_classification huggingface dataset:
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Actinic Keratosis Subjects must be competent to understand the nature of the trial and provide informed consent Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp Subject at least 18 years of age Female subjects must be of either Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy Female subjects of childbearing potential must be willing to use effective contraception  Location of the selected treatment area on any location other than the face or scalp within 5 cm of an incompletely healed wound within 10 cm of a suspected basal cell carcinoma (BCC) or SCC Prior treatment with PEP005 Gel on face or scalp Selected treatment area lesions that have atypical clinical appearance and/or recalcitrant disease History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postpolypectomy Bleeding Patients with one or more pedunculated polyps, the heads of which measured more than 1cm (regardless of the stalk thickness and length), and they were compared against the size of the biopsy forceps (6mm) and subsequently confirmed in the anatomical specimen Not to have any hemostatic alterations at the time the endoscopy was performed (confirmed by the usual blood tests taken before the procedure)  Patients younger than 18 years of age Patients with a platelet count of less than 50000, INR larger than 1.5 Patients who refused to give their informed consent
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Non-palpable Breast Lesions Have had stereotactic or ultrasound-guided biopsy with marker placement Have a lesion or biopsy marker that is visible under ultrasound Have surgical target < 6 cm from the skin when lying supine Have a discreet surgical target Have a lesion in which the center/focal area is defined Be at least 18 years of age or older  Have a palpable lesion that does not require localization Require more than one localization needle for localization of the surgical target Have undergone previous open surgical biopsy or lumpectomy in the operative breast Have an implant in the operative breast Have a cardiac pacemaker or defibrillator device
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Basal Cell Carcinoma (BCC) Patients over 60 years old BCC was determined with tissue diagnosis in the lower extremity One or more risk factor for surgical complication including: diabetes, venous insufficiency, obesity, peripheral vascular disease, lymphedema and long term steroids use  Patient unable to read, understand and sign the consent form
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Wide-neck, Saccular Intracranial Aneurysms At least 18 years old A wide-neck intracranial saccular aneurysm with a neck ≥ 4mm or a dome to neck ratio <2 in the ICA from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments) Life expectancy > 12 months Signed Informed Consent  Females who are pregnant or intend to become pregnant during the study. (Females of child-bearing potential must have a urinary pregnancy test within 7 days of enrollment) Extradural aneurysms Known multiple untreated cerebral aneurysms at study entry Recent history of subarachnoid hemorrhage, intracranial hemorrhage, or major surgery within one month of enrollment Admission platelet <50,000 or any known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy with an INR >3.0 Contraindication to angiography such as elevated creatinine or known allergy to angiographic contrast Contraindication to CT and/or MRI scans Known allergy to the metal component of the Penumbra Liberty Stent System Evidence of active infection (WBC >10x109 /L) Any medical conditions that will not allow the necessary follow-up for this study (e.g., pre-existing neurological or psychiatric diseases)
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-melanocytic Skin Tumors Melanocytic Skin Tumors seborrhoeic warts nevi dermatofibroma basal cell carcinoma actinic keratosis squamous cell carcinoma Bowen's disease Merkel cell carcinoma malignant melanoma  employers of the Medical University of Vienna patients during compulsory military service patients with an appointed guardian
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Clinically Atypical Pigmented Skin Lesion Cutaneous lesions examined with MelaFind must satisfy all of the following The lesion is pigmented (i.e., melanin, keratin, blood) The diameter of the pigmented area is not < 2 mm, and not > 22 mm The lesion is accessible to the MelaFind The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form Cutaneous lesions that meet any of the following  will not be accepted The patient has a known allergy to isopropyl alcohol The lesion has been previously biopsied, excised, or traumatized The skin is not intact (e.g., open sores, ulcers, bleeding) The lesion is within 1 cm of the eye The lesion is on mucosal surfaces (e.g., lips, genitals) The lesion is on palmar hands The lesion is on plantar feet The lesion is on or under nails The lesion is located on or in an area of visible scarring
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Colorectal Polyp pedunculated colorectal polyps larger than 2cm in diameter long-term antiplatelet therapy  presence of intraepithelial
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Body Temperature Changes belong to ethnic groups requested  suffering any change in skin sensitivity, illness of an infectious nature or previously diagnosed diseases that respond negatively to the use of cold
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Keloid Cicatrix, Hypertrophic Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr) A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks Patients with all Fitzpatrick17 skin types Patients older than 10 years of age  pregnancy diabetes mellitus
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Postprandial Glycemia Age 18-45 Male No regular medication No participation in a drug trial or blood donation within 2 months Non-smoker Signs informed consent Body mass index 18.5-27 kg/m2 Fasting plasma cholesterol < 5.5 mmol/l Fasting plasma triacylglycerols < 2.6 mmol/l Fasting plasma glucose 4-6 mmol/l  Regular smoking Alcohol abuse Regular medication
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Foreign Object Accidentally Left in Body During Surgical and Medical Care Healthy men and women Ages 18 or older -  Under 18 years of age Pregnant female or if female has not had a negative pregnancy test prior to the research scans
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Keloid Cicatrix Hypertrophic Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr) A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks Patients with all Fitzpatrick17 skin types Patients older than 10 years of age  pregnancy diabetes mellitus
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 35.0-70.0,  Skin Aging female gender age > 35 years old good general state of health woman who had already undergone Hyaluronic acid injections woman who have not applied any retinoid product in the last 3 months woman who are not in a recovery period after laser/peeling/acne treatment accepting to return to the centre for the planned visits accepting to follow the investigator's instructions during the entire study period agreeing to present at each study visit without make-up accepting to not change their habits regarding: food, physical activity, face cleansing and make-up use  Pregnancy (only for subjects not in menopause) lactation (only for subjects not in menopause) subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study subjects not in menopause who do not accept to perform the pregnancy test during the basal visit (T0), 6 and 12 weeks after the intradermal implant execution subjects participating to a similar test less than 3 months ago sensitivity to the test products or theirs ingredients subjects whose insufficient adhesion to the study protocol is foreseeable dermatitis presence of cutaneous disease on the tested area as lesions, scars, malformations clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.)
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  External Genital Warts Adults at least 18 years old with at least two visible EGWs Subject must be in good general health as confirmed by the medical history Subject must be able to read, sign, and understand the informed consent Subject must be willing to forego any other treatments for his/her EGW lesions Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study  Subject with any evidence of herpes genitalis or any other current and/or recurrent genital or uncontrolled infection, including Human Immunodeficiency Virus, Hepatitis B or Hepatitis C Subject with an unstable medical condition as deemed by the clinical investigator Subject with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of EGW lesions Subject who has previously been treated in an EGW clinical trial, had treatment of anogenital warts or had systemic intake of virostatics or immunosuppressive medication within 30 days prior to Baseline Visit Women who are pregnant, lactating, or planning to become pregnant during the study period Subject who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc) Subject who have active chemical dependency or alcoholism as assessed by the investigator Subject who have known allergies to any component of the study ointment Subject who have organ allograft, skin conditions that may interfere with study ointment, or having internal (vaginal or rectal) warts that have required treatment Subject who has received any of the following within 90 days prior to study treatment initiation
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bleeding Patients with pedunculated colorectal polyps, the heads of which were larger than 10mm and the stalk of which were large than 5 mm in diameter, were included  bleeding tendency, poor preparation, sessile polyp
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Seborrheic Keratosis Subject is at least 18 years of age Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis Subject has 4 appropriate seborrheic keratosis target lesions, as defined below (Section 5.4), on the trunk/extremities Have a clinically typical appearance Be treatment naïve Have a PLA of ≥2 (Section 6.1.2) Have a longest axis that is ≥7mm and ≤15mm (Section 6.1.3) Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm (Section 6.1.3) Have a thickness that is ≤3mm Be a discrete lesion  Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser-Trelat) Subject has a current systemic malignancy Subject has a history of keloid formation or hypertrophic scarring Subject has used any of the following systemic therapies within the specified period prior to Visit 1 Retinoids; 180 days Glucocorticosteroids; 28 days Anti-metabolites (e.g., methotrexate); 28 days Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, that in the investigator's opinion, interferes with the application of the study medication or the study assessments LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]) or other energy based therapy; 180 days
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Melanoma All patients referred to the Dermatology Department, Lanarkshire Hospitals during a period to be defined for assessment of suspicious skin lesions (cutaneous moles) will be eligible for in the study. There are no age limits but patients under the age of 18 years will also have their subject to parental/guardian consent  There is no exclsion
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain Micrometastases Adult patients with brain metastasis from any primary tumour receiving GKR All intracranial micro-metastases including lesions located in the cerebral hemispheres, thalamus, basal ganglia and cerebellum and excluding lesions located in the brain stem below the level of the superior colliculi Target volume < 0.14 cc3 and maximum diameter < 7 mm The subject consents to participate in the study  Inability to consent Younger than 18 years of age Lesions in the brainstem (below the level of the superior colliculi) are better treated with the 4 mm collimator and they will be excluded from the study Patients with more than 25 brain lesions suitable for randomisation will be excluded from the study Co-morbidity or previous treatment such as surgery, chemotherapy or WBRT is not to be considered as Pregnancy in the context of brain metastases is not a contraindication for GKR, and therefore it will not be considered as for this trial
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Seborrheic Keratosis Subject is at least 18 years of age Subject has a Fitzpatrick skin type of 1-4 Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis Subject has 1 appropriate seborrheic keratosis target lesion, as defined below (Section 5.4), on the face Have a clinically typical appearance Be treatment naïve Have a PLA of ≥2 (Section 6.1.2) Have a longest axis that is ≥7mm and ≤15mm (Section 5.4) Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm (Section 5.4) Have a thickness that is ≤2mm  Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser-Trelat) Subject has a current systemic malignancy Subject has a history of keloid formation or hypertrophic scarring Subject has used any of the following systemic therapies within the specified period prior to Visit 1 Retinoids; 180 days Glucocortico-steroids; 28 days Anti-metabolites (e.g., methotrexate); 28 days Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, which in the investigator's opinion, interferes with the application of the study medication or the study assessments LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]) or other energy based therapy; 180 days
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Keratosis, Seborrheic Subjects are Caucasian or Asian Subjects who are between 18-65 year olds Subjects have flat or macular seborrheic keratosis on dorsum of the hands and wrists, extensor surfaces of the forearms. The diagnosis of flat seborrheic keratosis is confirmed by two clinical dermatologists using routine clinical examination and dermoscopy Subjects have Fitzpatrick skin type I-III Subjects are in good health Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator  History of keloids or hypertrophic scars Pregnant or lactating or intends to become pregnant in the next 3 months Active skin disease or skin infection in the treatment area Previous history of lidocaine allergy History of methemoglobinemia Unable to understand the protocol or to give informed consent Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical study or would pose as an unacceptable risk to subject